Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Polycystic Ovary Syndrome 1Cardiovascular Diseases 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Raloxifene Hydrochloride × Clear all
NCT00687102 2018-09-12

Co-STAR

Wake Forest University Health Sciences

Phase 3 Completed
1,498 enrolled 13 charts
Breast

Breast Neoplasms

NCT00003906 2015-10-06

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

NSABP Foundation Inc

Phase 3 Completed
19,747 enrolled
Breast

Breast Neoplasms

NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡